Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000755 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
168
Enrollment target
10
Study locations

NCT00000755 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 168 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000755, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
168 participants
Enrollment target
10
Study locations

Study Summary

To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • BIOLOGICAL rgp120/HIV-1MN

Study Locations (10)

Massachusetts

  • Massachusetts General Hospital ACTG CRS - Boston
  • Bmc Actg Crs - Boston
  • Beth Israel Deaconess - East Campus A0102 CRS - Boston
  • Beth Israel Deaconess Med. Ctr., ACTG CRS - Boston

California

  • UCLA CARE Center CRS - Los Angeles
  • Stanford CRS - Palo Alto
  • Ucsf Aids Crs - San Francisco

Colorado

  • University of Colorado Hospital CRS - Aurora

New York

  • NY Univ. HIV/AIDS CRS - New York

Washington

  • University of Washington AIDS CRS - Seattle

Trial Details

FieldValue
Enrollment Target 168 participants
Est. Completion 1993-03
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000755

The ClinicalTrials.gov registry entry for NCT00000755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.

NCT00000755 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00000755 about?

NCT00000755 is a clinical study titled "A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3". To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immun...

What is the current status of trial NCT00000755?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. Estimated completion is 1993-03.

What conditions does trial NCT00000755 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000755?

The interventions under investigation include: Zidovudine (DRUG), rgp120/HIV-1MN (BIOLOGICAL).

Who is sponsoring clinical trial NCT00000755?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000755 being conducted?

This trial has 10 study locations across California, Colorado, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.